Share Twitter LinkedIn Facebook Email Andrew Krivoshik, MD of @AstellasUS discusses the EV_103 phase I trial in locally advanced and first- and second-line metastatic urothelial cancer. #ESMO2019
FDA Approves New Bladder Cancer Therapy: A Look at Anktiva Nogapendekin Alfa Inbakicept-pmln Bladder 4 Mins Read
